BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23244593)

  • 21. [In vitro comparison of thienorphine metabolism in liver microsomes of human, Beagle dog and rat].
    Deng JT; Zhuang XM; Li H
    Yao Xue Xue Bao; 2010 Jan; 45(1):98-103. PubMed ID: 21351457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous determination of MK-0767 and seven metabolites in rat urine using liquid chromatography/tandem mass spectrometry.
    Shen Z; Kochansky C; Bakhtiar R; Franklin RB; Vincent SH
    Rapid Commun Mass Spectrom; 2004; 18(18):2113-20. PubMed ID: 15317046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in vitro microdialysis methodology to study 11beta-hydroxysteroid dehydrogenase type 1 enzyme activity in liver microsomes.
    Sun L; Stenken JA; Yang AY; Zhao JJ; Musson DG
    Anal Biochem; 2007 Nov; 370(1):26-37. PubMed ID: 17765862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitation of parent drug and its unstable metabolites by in situ coulometric oxidation and liquid chromatography-tandem mass spectrometry.
    Tong W; Chowdhury SK; Su AD; Alton KB
    Anal Chem; 2010 Dec; 82(24):10251-7. PubMed ID: 21105697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.
    Cheng Y; Wang L; Iacono L; Zhang D; Chen W; Gong J; Humphreys WG; Gan J
    Br J Clin Pharmacol; 2018 Jan; 84(1):130-141. PubMed ID: 28850715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo metabolism of desogestrel in several species.
    Verhoeven CH; Krebbers SF; Wagenaars GN; Vos RM
    Drug Metab Dispos; 1998 Sep; 26(9):927-36. PubMed ID: 9733673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
    Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
    Christopher LJ; Cui D; Li W; Barros A; Arora VK; Zhang H; Wang L; Zhang D; Manning JA; He K; Fletcher AM; Ogan M; Lago M; Bonacorsi SJ; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2008 Jul; 36(7):1341-56. PubMed ID: 18420785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and 11β hydroxysteroid dehydrogenase 1 inhibition of thiazolidine derivatives with an adamantyl group.
    Kwon SW; Kang SK; Lee JH; Bok JH; Kim CH; Dal Rhee S; Jung WH; Kim HY; Bae MA; Song JS; Ha DC; Cheon HG; Kim KY; Ahn JH
    Bioorg Med Chem Lett; 2011 Jan; 21(1):435-9. PubMed ID: 21093259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative metabolism and stability of andrographolide in liver microsomes from humans, dogs and rats using ultra-performance liquid chromatography coupled with triple-quadrupole and Fourier transform ion cyclotron resonance mass spectrometry.
    Zhao HY; Hu H; Wang YT
    Rapid Commun Mass Spectrom; 2013 Jun; 27(12):1385-92. PubMed ID: 23681817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.
    Dean BJ; Chang S; Silva Elipe MV; Xia YQ; Braun M; Soli E; Zhao Y; Franklin RB; Karanam B
    Drug Metab Dispos; 2007 Feb; 35(2):283-92. PubMed ID: 17132765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
    Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ
    Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
    Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
    Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
    Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations.
    Ehlhardt WJ; Woodland JM; Baughman TM; Vandenbranden M; Wrighton SA; Kroin JS; Norman BH; Maple SR
    Drug Metab Dispos; 1998 Jan; 26(1):42-51. PubMed ID: 9443851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative estimation of circulating metabolites without synthetic standards by ultra-high-performance liquid chromatography/high resolution accurate mass spectrometry in combination with UV correction.
    Yang Y; Grubb MF; Luk CE; Humphreys WG; Josephs JL
    Rapid Commun Mass Spectrom; 2011 Nov; 25(21):3245-51. PubMed ID: 22006386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.